SCHEMBL446800

SCHEMBL446800

C[CH]OCC1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5229 0.97 CYP1A2 (0.36)
SCHEMBL5385 0.97 CYP1A2 (0.36)
SCHEMBL4977 0.97 CYP1A2 (0.36)
SCHEMBL5167 0.95
SCHEMBL131688 0.89
SCHEMBL11291566 0.78 CTSL (0.33)
SCHEMBL5271829 0.78 CTSL (0.33)
SCHEMBL5271827 0.78 CTSL (0.33)
SCHEMBL14463380 0.78 CTSL (0.33)
SCHEMBL11226145 0.78 CTSL (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024062300-A1 BIODEGRADABLE ELASTOMERIC COPOLYMER SDIP Innovations Pty Ltd (AU) 2024-03-28 WO disclosed
US-20230109663-A1 CONJUGATED POLYMERS AND METHODS OF USE BioLegend, Inc. (US) 2023-04-06 US disclosed
US-11584883-B2 Conjugated polymers and methods of use BioLegend, Inc. (US) 2023-02-21 US disclosed
EP-3974496-B1 CONJUGATED POLYMERS AND METHODS OF USE BIOLEGEND INC (US) 2022-12-14 EP disclosed
US-20220002552-A1 SUBSTITUTED POLYFLUORENE COMPOUNDS BioLegend, Inc. (US) 2022-01-06 US disclosed
EP-3658648-B1 CONJUGATED POLYMERS AND METHODS OF USE BIOLEGEND INC (US) 2021-10-27 EP disclosed
US-11155714-B2 Substituted polyfluorene compounds BioLegend, Inc. (US) 2021-10-26 US disclosed
EP-3590940-B1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES HOFFMANN LA ROCHE (CH) 2021-06-09 EP disclosed
US-10988687-B2 Phthalocyanine formulation and uses thereof LI-COR, INC. (US) 2021-04-27 US disclosed
US-10913745-B2 Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors HOFFMANN-LA ROCHE INC. (US) 2021-02-09 US disclosed
WO-1999067228-A1 FLUOROPHENYL RESIN COMPOUNDS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-12-29 WO disclosed
EP-0960096-A1 SUBSTITUTED $g(b)-THIOCARBOXYLIC ACIDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-12-01 EP disclosed
WO-1999048870-A1 PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-09-30 WO disclosed
WO-1999038844-A1 METHOD FOR PREPARING AN N-[(ALIPHATIC OR AROMATIC)CARBONYL]-2-AMINOACETAMIDE COMPOUND AND A CYCLYZED COMPOUND AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-08-05 WO disclosed
EP-0871439-A4 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE POULENC RORER PHARMA (US) 1999-07-21 EP disclosed
WO-1999031491-A1 METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-06-24 WO disclosed
WO-1999025752-A1 FUNCTIONALIZED RESIN FOR THE SYNTHESIS OF AMIDES AND PEPTIDES AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-05-27 WO disclosed
EP-0871439-A1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1998-10-21 EP disclosed
WO-1998032734-A1 SUBSTITUTED β-THIOCARBOXYLIC ACIDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-07-30 WO disclosed
WO-1997024117-A1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-10 WO disclosed